International Modern Hospital in Dubai awarded Australian Healthcare Accreditation gulfnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gulfnews.com Daily Mail and Mail on Sunday newspapers.
/Corporate Wellness Software Market Set to Witness Huge Growth by 2026 | Centers for Medicare & Medicaid Services, US Department of Health & Human Services
Corporate Wellness Software Market Set to Witness Huge Growth by 2026 | Centers for Medicare & Medicaid Services, US Department of Health & Human Services
triMay 4, 2021 5
Corporate Wellness Software Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.
Patients weigh in on GPs, dentists, private health insurance, healthcare costs and more
Despite a once-in-a-century pandemic still lingering one year on, Australians have given a vote of confidence to the Australian healthcare system with 65.5% rating it a score of 8 or above out of 10 in a new report capturing the points of view of Australian patients.
The first Australian Healthcare Index report seeks to elevate patient perspectives and experiences on overall healthcare in Australia, based on responses from over 8000 adults.
Produced by the Australian Patients Association and HealthEngine, the report captures learnings from patients on the public and private healthcare ecosystem including primary care, private health insurance (PHI), emergency departments, elective surgery, prescription medicine and more.
Xlife Sciences AG: Transaction with Baliopharm AG
Search jobs
Xlife Sciences AG / Key word(s): Contract
Xlife Sciences AG: Transaction with Baliopharm AG
08-Jan-2021 / 06:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Xlife Sciences AG: Transaction with Baliopharm AG
License Deal of 300 million euros successfully completed
Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based company is a leader in innovative antibody therapies for the treatment of acute and chronic inflammatory diseases.